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Bronchioloalveolar Carcinoma Is Not Associated with
Younger Age at Diagnosis: An Analysis of the SEER
Database
Dan J. Raz, MD, and David M. Jablons, MD
Introduction: Bronchioloalveolar carcinoma (BAC) is a unique
subtype of non-small cell lung cancer (NSCLC) that is associated
with female gender, Asian ethnicity, and never-smoking status.
Although BAC is commonly reported to occur more frequently in
young people with lung cancer, there is a lack of evidence to support
this association.
Methods:We analyzed the association between age at diagnosis and
NSCLC histology among 293,417 incident cases of NSCLC in the
Surveillance Epidemiology, and End Results (SEER) database dur-
ing the years 1973 to 2002.
Results: The mean age of patients with BAC (66.99 years) was
similar to the mean age of all patients with NSCLC (66.44 years).
The proportion of patients younger than 50 years of age was
significantly smaller among patients with BAC than the overall
cohort (6.06% compared with 6.90%). Although a greater percent-
age of women and Asian patients with lung cancer were younger
than 50 years old, the proportion of patients with BAC was similar
to the proportion of men and non-Asians with BAC. Finally, the
prevalence of BAC histology among patients younger than 50 years
did not change significantly after revision of the 1999 World Health
Organization pathologic criteria for the diagnosis of BAC (risk ratio
0.93 versus 0.87, p  0.31).
Conclusion: BAC is not associated with a younger mean age at
diagnosis, nor is it associated with an age of less than 50 years at
diagnosis. Patients with mixed BAC probably have similar age
characteristics compared with patients with pure BAC.
Key Words: Bronchioloalveolar carcinoma, Epidemiology, Age,
Lung cancer.
(J Thorac Oncol. 2006;1: 339–343)
Bronchioloalveolar carcinoma (BAC) is a subtype of non-small cell lung carcinoma (NSCLC) with a unique histo-
pathology, tumor biology, clinical course, and response to
treatment. Interest in BAC has grown amid reports that the
incidence of BAC may be rising1,2 and that BAC histology
may predict response to the epidermal growth factor tyrosine
kinase inhibitors gefitinib (Iressa; AstraZeneca Pharmaceuti-
cals, Wilmington, DE) and erlotinib (Tarceva; OSI Pharma-
ceuticals, Melville, NY).3–5 Patients with BAC are more
likely to be women, Asians, and never-smokers compared
with patients with other subtypes of NSCLC.3,6–8
There is a prevailing notion that BAC disproportion-
ately affects younger patients; however, there is no strong
evidence that patients with BAC are younger than those with
other subtypes of NSCLC, nor is there evidence that younger
patients with lung cancer are more likely to have BAC.
Whereas several single-institution series have reported a
younger mean age for BAC compared with other NSCLC
histologies,2,9,10 other series have shown no difference in
mean age.11,12 In one of the most widely cited studies on the
epidemiology of BAC, Barsky et al.2 reported a mean age of
59 years among 187 patients with BAC, which was signifi-
cantly lower than the mean age of 64 years for patients with
non-BAC adenocarcinomas. Meanwhile, Read et al.13 found
no difference between the mean age of patients with BAC
compared with all patients with lung cancer in the Surveil-
lance Epidemiology and End Results (SEER) database
through 1998. Data from another population-based study of
patients in a large cancer registry also suggest that the mean
age among patients with BAC is similar to the mean age of
patients with other subtypes of NSCLC.14 No large series
specifically examining the possible association between pa-
tient age and lung cancer histology has been recently pub-
lished.
We used the SEER database to determine whether
patients with BAC were younger than other patients with lung
cancer and whether young people with lung cancer were more
likely to have BAC. Because BAC is associated with female
gender and Asian ethnicity, we also wanted to determine
whether women and Asians were more likely to be younger
than men and non-Asians and whether there was any inter-
action with gender or ethnicity in the possible association
between BAC and younger age. Finally, we examined
whether there were temporal trends in the age at diagnosis of
patients with BAC during the almost 30-year period captured
in the SEER database. Specifically, we wanted to determine
whether age characteristics changed in 1999, when the World
Health Organization revised the criteria for the diagnosis of
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BAC, restricting the diagnosis to tumors without any histo-
logic invasion.15
MATERIALS AND METHODS
We used SEER public-use data (1973-2002), released
April 2005, and downloaded from http://seer.cancer.gov. The
database is maintained by the National Cancer Institute, and
the catchment areas for the database have been expanded
successively since 1972. More information on the geographic
areas included in the database can be found on the SEER
website.
Tumor histology in the database are classified by In-
ternational Classification of Disease 0-3 codes. Histology
codes were categorized by major NSCLC histology subgroup
as follows: BAC (8250-8255), adenocarcinoma (non-BAC:
8140-8141, 8143, 8147, 8250-8255, 8260, 8480-8481, 8550-
8551, 8560, 8562), squamous cell carcinoma (8050-8052,
8070-8078), and other NSCLC (8012, 8013, 8020-8022,
8030, 8031, 8046). The vast majority of tumors in the “other
NSCLC” category were large cell carcinoma and undifferen-
tiated NSCLC. Based on these histologic diagnoses, we
identified 293,417 patients with NSCLC, of whom 13,859
had BAC. Patients were categorized as Asian or non-Asian
based on ethnicity information in the SEER database.
Data were analyzed using STATA version 9.1. Mean
age of diagnosis was determined for the entire cohort and for
each major histology group. Mean age for each major histol-
ogy group was determined for female NSCLC patients and
Asian NSCLC patients. Mean ages were compared using an
analysis of variance followed by the Holmes-Sidak t-test to
isolate differences.
The incidence of BAC and the other major histologic
subtypes of NSCLC was stratified by decade of age for
comparison. Patients were then stratified by age younger than
50 years to look for a difference in incidence among histo-
logic subtypes and by race and gender. A cutoff of 50 years
was used after consensus with lung cancer practitioners at our
institution as best describing the age at which patients with
lung cancer are considered young. Risk ratios for the major
histologic subtypes of NSCLC were calculated and compared
with the reference risk ratio (all cases of NSCLC) using the
Pearson 2 test.
The incidence of BAC among women and Asians was
stratified by age younger than 50 years. The Pearson 2 test
was used to compare incidence between men and women, and
Asians and non-Asians. A multiple logistic regression was
performed to model predictors of BAC incorporating avail-
able variables in the database, including age younger than 50
years, gender, and Asian ethnicity. Odds ratios and 95%
confidence intervals (CIs) were calculated.
The incidence of BAC among all patients, as well as
patients younger than 50 years, during each year for which
the SEER database reported data (1973–2002) was calculated
to assess for temporal trends. Data were then stratified by
years 1973–1998 and 1999–2002 to determine whether there
were changes in the age distribution of patients with BAC
before and after the World Health Organization revised its
diagnostic criteria in 1999. Overall and NSCLC subtype-
specific mean ages were calculated and compared between
the time periods using a paired t-test. The proportion of
patients younger than 50 years was calculated in the entire
cohort and among the histologic subtypes and compared
between the two time periods using the Pearson 2 test. Risk
ratios for age younger than 50 years were determined for each
histology subtype and stratified by time period. Strata-spe-
cific risk ratios were compared using the Mantel-Hanzel test
of homogeneity.
RESULTS
The mean (SD) age of the 293,417 patients with
NSCLC was 66.44  10.77 years; it was 66.99  10.66 for
the 13,859 patients with BAC. Mean ages for the other major
histologic subtypes are listed in Table 1. The mean ages were
not meaningfully different, although they were statistically
significantly different because of the large sample size.
The percentage of patients younger than 50 years of age
was determined in the entire cohort and among each major
histology group and is summarized in Table 1. Overall,
TABLE 1. Analysis of Age and NSCLC in the SEER Database
Age at diagnosis (years)
All NSCLC 66.44  10.77
BAC 66.99  10.66
Adenocarcinoma 65.59  11.26
Squamous cell 67.63  9.96
Other NSCLC 65.77  11.05
Patients 50 years of age (%) Risk ratio (95% CI)a p value*
All NSCLC 6.90 1.00
BAC 6.06 0.88 (0.82–0.94) 0.0001
Adenocarcinoma 8.64 1.28 (1.26–1.29) 0.0001
Squamous cell 4.45 0.63 (0.61–0.64) 0.0001
Other NSCLC 8.26 1.21 (1.18–1.25) 0.0001
NSCLC, non-small cell lung cancer; BAC, bronchioloalveolar carcinoma. a Risk of NSCLC among patients younger than
50 years of age compared with all patients with NSCLC. *p value is for the 2 test for which the calculated risk ratio differs
from 1.0.
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6.90% of patients with NSCLC were younger than 50 years,
compared with 6.06% of patients with BAC and 8.64% of
patients with adenocarcinoma. Among patients with NSCLC,
those with BAC were less likely to be younger than 50 years
(RR 0.88, 95% CI 0.82–0.94; p  0.0001), whereas those
with adenocarcinoma were more likely to be younger than 50
years (RR 1.28, 95% CI 1.26–1.29; p  0.0001).
Next we analyzed the age at diagnosis of women and
Asians with lung cancer, because these characteristics are
known to be associated with BAC histology (Table 2). The
mean age of the 108,482 women in the cohort was 66.33 
11.27, and the mean age of the 7,445 women with BAC was
66.86  10.94. The mean age of the 15,908 Asians in the
cohort was 66.74  11.61, and the mean age of the 1,215
Asians with BAC was 66.47  11.29. Women and Asians
with lung cancer were more likely to be younger than 50
years at diagnosis. Of the women with NSCLC, 8.04% were
younger than 50 years, 6.81% of women with BAC were
younger than 50 years, and 9.51% of women with adenocar-
cinoma were younger than 50 years. Of Asians with NSCLC,
8.33% were younger than 50 years, 7.82% of Asians with
BAC were younger than 50 years, and 9.71% of Asians with
adenocarcinoma were younger than 50 years. However, race
and gender did not modify the risk of being younger than 50
years among patients with BAC. In other words, women and
Asians younger than 50 years were no more likely to have
BAC than men or non-Asians (test of homogeneity: p  0.47
for Asian ethnicity, p  0.95 for female gender).
We performed multivariate analysis of the risk of BAC
histology, adjusting for female gender, Asian race, and age
younger than 50 years (Table 3). Patients with BAC were
more likely to be female (adjusted odds ratio [OR] 2.06, 95%
CI 1.99–2.14) and Asian (adjusted OR 1.76, 95% CI 1.66–
1.97) but actually less likely to be younger than 50 years (OR
0.82, 95% CI 0.77–0.88).
The incidence of the major histologic subtypes of
NSCLC was further stratified by decade of age (Figure 1).
The proportion of patients with BAC and the proportion
of patients with BAC younger than 50 years of age were
determined yearly from 1973 to 2002 (Figure 2). Data were
then stratified by histologic subtype and by years 1973–1998
(n  238,313) and 1999–2002 (n  55,104) to examine for
any effect of the revised World Health Organization histo-
logic criteria for BAC in 1999 (Table 4). The overall and
histologic subtype specific mean ages were slightly higher
during 1999–2002 (68.39 versus 65.99 years among all
patients with NSCLC and 68.64 versus 66.52 years among
patients with BAC). The percentage of patients younger than
50 years during 1999–2002 was lower in the entire cohort
and for each histologic subtype (5.82% versus 7.15% among
all patients with NSCLC; 5.53% versus 6.27% among pa-
tients with BAC). When stratified by time period, the RR of
BAC among patients younger than 50 years was not signifi-
cantly different: 0.87 (95% CI 0.80–0.94) for 1973–1998
compared with 0.95 (95% CI 0.81–1.10) for 1999-2002 (p 
0.31). The RR of adenocarcinoma among patients younger
than 50 years was also not significantly different (1.28 versus
1.27, p  0.50).
DISCUSSION
Our findings, using a very large multi-institutional
cohort of patients with lung cancer, provide strong evidence
that BAC is not associated with younger age at diagnosis. The
mean age of patients with BAC was not meaningfully differ-
ent from other subtypes of lung cancers, confirming data from
Read et al.13 and Zell et al.14 The proportion of patients with
BAC who were younger than 50 years of age at diagnosis was
slightly less than the proportion of patients younger than 50
years of age with all types of NSCLC. Similarly, when we
stratified the patients by gender and Asian ethnicity, we found
no difference in the mean age or in the proportion of patients
younger than 50 years of age with BAC compared with other
types of NSCLC. In a multivariate model of BAC incorpo-
rating gender, ethnicity, and age, age younger than 50 years
was not significantly associated with increased risk of BAC
histology among patients with lung cancer. Whereas women
and Asians are more likely to have BAC, young patients with
lung cancer actually have a slightly decreased chance of
having BAC and have a higher chance of having non-BAC
adenocarcinoma.
TABLE 2. Age of Women and Asians with NSCLC
Mean age (years)
Women Asians
Total NSCLC 66.33  11.27 66.74  11.61
BAC 66.86  10.94 66.47  11.29
Adenocarcinoma 65.63  11.69 66.12  12.03
% of patients <50 years RR of age <50 years*
Women Asians Women p value Asians p value
Total NSCLC 8.04 8.33
BAC 6.81 7.82 0.84 (0.77–0.91) 0.001 0.93 (0.76–1.14) 0.5
Adenocarcinoma 9.51 9.71 1.20 (1.18–1.22) 0.001 1.18 (1.12–1.25) 0.001
NSCLC, non-small cell lung cancer; BAC, bronchioloalveolar carcinoma; RR, risk ratio. *2 test testing that RR  1.
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There was also no meaningful change in the percentage
of patients with BAC younger than 50 years between 1973
and 2002. There has actually been a slight decrease in the rate
of lung cancers in patients younger than 50 years reported in
the SEER database since 1998.
An important limitation of the SEER database is that
histologic diagnoses cannot be confirmed by independent
pathologists. Because patients are entered into the database
based on histology diagnosis code, we would expect that the
diagnosis of BAC applies only to patients with pure BAC, as
opposed to mixed BAC and adenocarcinoma. This classifi-
cation scheme accounts for the relatively low proportion of
TABLE 4. Comparison of data by time period
Mean Age (SD)
1973–1998 1999–2001 p value*
(n  238,313) (n  55,104)
All NSCLC 65.99  10.66 68.39  11.03 0.001
BAC 66.52  10.54 68.64  10.90 0.001
Adenocarcinoma 65.10  11.14 67.55  11.52 0.001
Patients 50 years (%)
1973–1998 1999–2001 p value†
(n  17,042) (n  3,207)
All NSCLC 7.15 5.82 0.001
BAC 6.27 5.53 0.001
Adenocarcinoma 8.98 7.25 0.001
RR among patients 50 years
(RR [95% CI])§
1973–1998 1999–2001 p value‡
BAC 0.87 (0.80–0.94) 0.95 (0.81–1.10) 0.31
Adenocarcinoma 1.28 (1.26–1.30) 1.27 (1.22–1.31) 0.5
NSCLC, non-small cell lung cancer; BAC, BAC, bronchioloalveolar carcinoma; CI, confidence intervals. *p value is for a
paired t-test that tests the hypothesis that mean age was the same within groups. †p value is for a 2 test that tests the hypothesis
that the percentage of patients younger than 50 years was the same within groups. ‡p value is for the Mantel-Hanzel test of
homogeneity comparing time-specific risk ratios. §Risk ratios (RR) compare incidence among patients younger than 50 years
compared with patients older than 50 years.
TABLE 3. Multivariate model of predictors of BAC histology
Odds ratio (95% CI) p value
Age 50 years 0.82 (0.77–0.88) 0.001
Female 2.06 (1.99–2.14) 0.001
Asian ethnicity 1.76 (1.66–1.97) 0.001
CI, confidence interval.
FIGURE 1. Percentage of NSCLC major histologic subtypes
within each age group. A total of 293,417 patients with
non-small cell lung cancer from the SEER database were
included.
FIGURE 2. Temporal trends in the incidence of bronchi-
oloalveolar carcinoma (BAC) among patients with lung can-
cer who were younger than 50 years of age between 1973
and 2002, from the SEER database. Data include a total of
293,417 patients with non-small cell lung cancer (NSCLC),
of whom 13,859 had BAC. The blue line depicts the percent-
age of BAC among all patients with NSCLC diagnosed that
year. The red line depicts the percentage of BAC among pa-
tients with NSCLC younger than 50 years diagnosed that
year.
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patients with BAC compared with several small published
series that estimate the incidence of BAC, both pure and
mixed, to be closer to 20%.1,2,7 Our results are valid for
patients with pure BAC. Although it does not seem plausible
that patients with mixed BAC and adenocarcinoma would be
younger than patients with pure BAC, patients with adeno-
carcinoma in this study were more likely to be younger than
50 years old at diagnosis than any other histology group. The
age breakdown of patients with mixed BAC histology who
were classified as having adenocarcinoma is unknown.
To determine whether patients with mixed BAC (clas-
sified as adenocarcinoma) differed in age from patients with
pure BAC (classified as BAC), we stratified patients accord-
ing to diagnosis before and after 1999, the year that the World
Health Organization criteria for BAC were revised to exclude
patients with an invasive component from being diagnosed
with BAC. We would expect that more patients diagnosed
before 1999 would have histologically mixed BAC. Thus, if
mixed BAC was associated with age younger than 50 years,
we would expect that the risk of BAC among patients
younger than 50 years in this very large cohort would be
greater before 1999. This was a strategy similar to that used
by Zell et al.14 in their population-based study examining the
survival of patients with BAC before and after the revision of
World Health Organization pathologic criterion for BAC in
1999. We found that there was no significant difference in
risk of BAC among patients with lung cancer younger than 50
years before and after 1999; in fact, there was a trend toward
a greater risk of BAC after 1999.
The lack of a World Health Organization-sanctioned
pathologic diagnosis for mixed BAC and adenocarcinoma has
resulted in non-uniform classification schemes in the litera-
ture as well as in cancer registries and the SEER data-
base.16–18 As a result, it is difficult to conduct multi-institu-
tional epidemiologic research into the apparent increase in
incidence in BAC, clinical research about the response of
patients with BAC to treatment, and basic science research
about the unique biology of BAC without a universally
accepted classification scheme for both pure and mixed BAC.
Although our data suggest that BAC is not associated
with younger age at diagnosis, patients with adenocarcinoma
were more likely to be younger than 50 years compared with
patients with other histologic subtypes (RR 1.28, p 
0.0001), and women and Asians with adenocarcinoma were
more likely to be younger than 50 years than men and
non-Asians. The etiology of the predisposition of younger
patients, especially women and Asians, to develop adenocar-
cinoma rather than squamous cell carcinoma is unknown and
warrants further investigation.
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